1 Dual agonism of GIP and GLP-1 receptors is a promising new approach currently in clinical development for the treatment of diabetes, obesity, and associated complications [1] The incretin effect defines the main physiological role of GIP and GLP-1 GIP and GLP-1 increase insulin secretion following nutrient-induced secretion from the gut (incretin effect): There is a stronger insulin secretion response to oral compared to 'isoglycemic' intravenous glucose administration due to secretion and action of incretin hormones
BFRs are synthetic flame retardants used in everyday products such as electrical and electronic devices, textiles, and furniture
(Patients, though, will probably pay out of pocket, as the medications wont be FDA-approved and are unlikely to be covered by insurance.) This vertically integrated, frictionless, moneymaking process is a far cry from the backroom of a 20th-century drugstore, where a pharmacist mixed up bespoke concoctions for patients in need
Target: 1,000 mcg total blend daily (~500 mcg each) by Weeks 38